Cross-sectional evaluation of a clinical decision support tool to identify medication-related problems at discharge from the acute care setting

被引:0
|
作者
Dicristina, Savanna [1 ,2 ,3 ,4 ]
Turgeon, Jacques [5 ,6 ]
Michaud, Veronique [5 ,6 ,7 ]
Brunetti, Luigi [1 ,2 ]
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Piscataway, NJ USA
[2] Robert Wood Johnson Barnabas Hlth RWJUH Somerset, Somerville, NJ USA
[3] Tabula Rasa HealthCare, Moorestown, NJ USA
[4] Northeastern Univ, Bouve Coll Hlth Sci, Sch Pharm & Pharmaceut Sci, Boston, MA USA
[5] GalenusRx, Orlando, FL USA
[6] Univ Montreal, Fac Pharm, Montreal, PQ, Canada
[7] CHU Montreal, Ctr Rech, CRCHUM, Montreal, PQ, Canada
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2024年 / 7卷 / 08期
关键词
clinical decision support systems; risk score; safety; ADVERSE DRUG-REACTIONS; PHARMACIST; IMPLEMENTATION; PROGRAM; SCORE; RISK;
D O I
10.1002/jac5.1998
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundThere are many reported pharmacist-led transitions of care (TOC) programs to address medication-related problems (MRP) at discharge from the acute care setting. Most have identified time and labor resources as significant limitations. This study aims to assess the effectiveness of a medication risk score (MRS)-driven clinical decision support system (CDSS) in identifying actionable MRPs and improving medication safety in the acute care discharge TOC setting.MethodsA cross-sectional analysis was conducted in a cohort of 481 subjects discharged from the acute care setting. The MRS-CDSS was utilized to identify MRPs and provide recommendations for risk reduction. The distribution of MRPs, recommendations, and their associations with MRS severity were analyzed. Additionally, the potential reduction in MRS per subject and its correlation with MRS severity were examined.ResultsThe median MRS reduction per subject was 2 points, while high/severe-risk patients showed a median potential reduction of 7 points. Among the identified MRPs (n = 691), drug interaction, drug use without indication, and adverse drug reaction accounted for 89.7% of all MRPs. The top three recommendations, discontinue medication, change the time of administration, and start alternative therapy, represented 94.1% of all recommendations. Stratified analysis by MRS category revealed a significant increase in adverse drug reaction MRPs and recommendations to discontinue medications with higher MRS severity. The results were consistent with previous outpatient studies, supporting the MRS-CDSS's ability to enhance medication safety.ConclusionThis study demonstrates that the MRS-CDSS effectively identifies actionable MRPs and has the potential to substantially reduce overall pharmacotherapy regimen risk when applied during acute care discharge TOC. The findings support implementable recommendations directed at patient safety and the allocation of health care resources to high-risk patients for maximum benefit.
引用
收藏
页码:763 / 771
页数:9
相关论文
共 50 条
  • [41] Call for Decision Support for High-Alert Medication Administration Among Pediatric Nurses: Findings From a Large, Multicenter, Cross-Sectional Survey in China
    He, Mengxue
    Huang, Qin
    Lu, Hong
    Gu, Ying
    Hu, Yan
    Zhang, Xiaobo
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] Call for Decision Support for High-Alert Medication Administration Among Pediatric Nurses: Findings From a Large, Multicenter, Cross-Sectional Survey in China
    He, Mengxue
    Huang, Qin
    Lu, Hong
    Gu, Ying
    Hu, Yan
    Zhang, Xiaobo
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] Medication use and drug-related problems among women at maternity wards-a cross-sectional study from two Norwegian hospitals
    Smedberg, J.
    Brathen, M.
    Waka, M. S.
    Jacobsen, A. F.
    Gjerdalen, G.
    Nordeng, H.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (07) : 849 - 857
  • [44] Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting
    Khanna, Puja P.
    Shiozawa, Aki
    Walker, Valery
    Bancroft, Tim
    Essoi, Breanna
    Akhras, Kasem S.
    Khanna, Dinesh
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 971 - 981
  • [45] Use of an Electronic Clinical Decision Support System in Primary Care to Assess Inappropriate Polypharmacy in Young Seniors With Multimorbidity: Observational, Descriptive, Cross-Sectional Study
    Rogero-Blanco, Eloisa
    Lopez-Rodriguez, Juan A.
    Sanz-Cuesta, Teresa
    Aza-Pascual-Salcedo, Mercedes
    Jose Bujalance-Zafra, M.
    Cura-Gonzalez, Isabel
    JMIR MEDICAL INFORMATICS, 2020, 8 (03)
  • [46] Evaluation of potentially drug-related patient-reported common symptoms assessed during clinical medication reviews, a cross-sectional observational study
    Schoenmakers, Tim
    Teichert, Martina
    Wensing, Michel
    de Smet, Peter
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (03) : 613 - 614
  • [47] Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study
    Tim W. A. Schoenmakers
    Martina Teichert
    Michel Wensing
    Peter A. G. M. de Smet
    Drug Safety, 2017, 40 : 419 - 430
  • [48] Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study
    Schoenmakers, Tim W. A.
    Teichert, Martina
    Wensing, Michel
    de Smet, Peter A. G. M.
    DRUG SAFETY, 2017, 40 (05) : 419 - 430
  • [49] Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: Results from the Indian subset data
    Pinjala, Ramakrishna
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2012, 136 (01) : 60 - 67
  • [50] Impact of pharmacist-evaluated clinical decision support system alerts on potentially missing or inappropriately prescribed proton pump inhibitors at hospital discharge: a retrospective cross-sectional study
    Flueckiger, Lee
    Zaugg, Claudia
    Fiumefreddo, Rico
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (05) : 1143 - 1151